Research Topic · Peer-Reviewed

Erythropoietin

Erythropoietin (EPO) is a hormone produced in the kidneys that stimulates the production of red blood cells in the bone marrow. It plays a crucial role in Hematology and Oncology Research as an important biomarker in the diagnosis and treatment of anemia, cancer, and chronic kidney disease. In patients with anemia,…

Curated from this journal's research 📚 3 peer-reviewed articles cited Cited 9× across the literature 🔖 ISSN 2372-6601 🗓 Reviewed July 2026

Overview

Erythropoietin (EPO) is a hormone produced in the kidneys that stimulates the production of red blood cells in the bone marrow. It plays a crucial role in Hematology and Oncology Research as an important biomarker in the diagnosis and treatment of anemia, cancer, and chronic kidney disease. In patients with anemia, EPO levels are low, and the administration of synthesized EPO increases the production of red blood cells, which can help to alleviate symptoms such as fatigue, shortness of breath, and weakness. EPO has also been shown to be beneficial in the treatment of cancer-related anemia, as it can reduce the need for blood transfusions and improve quality of life for cancer patients. Elevated EPO levels can be indicative of certain types of cancer, such as kidney cancer and hepatocellular carcinoma. In these cases, EPO serves as a useful biomarker for early detection and monitoring of disease progression. Research is currently being conducted to determine the potential of EPO as a cancer treatment by utilizing its ability to inhibit tumor angiogenesis. In addition, EPO has shown potential therapeutic effects in several non-hematologic conditions, such as cardiovascular disease, chronic obstructive pulmonary disease, and stroke. However, careful consideration is required when administering EPO due to the potential side effects, such as an increased risk of blood clots and hypertension. Overall, EPO is a vital hormone in Hematology and Oncology Research, serving as both a diagnostic tool and a potential treatment option for a range of conditions. Understanding the role of EPO in these areas is crucial for the advancement of medical research and the development of more effective treatments for patients.

Research published in this journal

3 peer-reviewed articles, ranked by relevance. Each links to its DOI.

How this research is being cited

The 3 articles above have been cited 9 times in the scholarly literature. Citation data via OpenAlex and Crossref, updated Jun 2026.

A sample of recent works citing this journal's research on Erythropoietin, linking to each citing work.

Editorial oversight

Curated from peer-reviewed research published in Hematology and Oncology Research (ISSN 2372-6601).

Journal editorial board
Jayadev Manikkam Umakanthan · United States Shuaiying Cui · United States Benedetto Sacchetti · Italy

This page summarises published research for orientation; it is not medical or professional advice.